(MT Newswires) -- Bristol-Myers (BMY) CEO Christopher Boerner discusses the company's transition, marked by a series of transactions and the development of new drugs, particularly in neuroscience and oncology. He talks about growth prospects, the pipeline of 16 new drugs in development between now and the end of the decade, and the return of capital to shareholders.

Bloomberg videos